Klin Farmakol Farm. 2023;37(2):68-71 | DOI: 10.36290/far.2023.012

Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug

Robert Prosecký1, Jiří Vítovec2
1 II. interní klinika FN u sv. Anny, Lékařská fakulta Masarykovy univerzity Brno
2 I. interní kardioangiologická klinika FN u sv. Anny, Lékařská fakulta Masarykovy univerzity, Brno

Tirzepatid is a drug developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It is a synthetic peptide that acts as a dual agonist of both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Its pharmacological properties stem from its ability to simultaneously activate these two receptors, which play an important role in the regulation of glucose metabolism and insulin secretion. In clinical studies, SURPASS has shown good efficacy in reducing glycated hemoglobin and reducing weight. It therefore appears to be a promising drug both in the treatment of type 2 DM and obesity.

Keywords: tirzepatide, obesity, type 2 DM, SURPASS.

Accepted: July 10, 2023; Published: July 10, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prosecký R, Vítovec J. Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug. Klin Farmakol Farm. 2023;37(2):68-71. doi: 10.36290/far.2023.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937-952. Go to original source... Go to PubMed...
    2. Cepeda-Valery B, Pressman GS, Figueredo VM, et al. Impact of obesity on total and cardiovascular mortality - fat or fiction? Nat Rev Cardiol. 2011;8(4):233-237. Go to original source... Go to PubMed...
    3. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-1010. Go to original source... Go to PubMed...
    4. Fontaine KR, Redden DT, Wang C, et al. Years of Life Lost Due to Obesity. JAMA. 2003;289(2):187. Go to original source... Go to PubMed...
    5. Vážná A, Vignerová J, Brabec M, et al. Influence of COVID-19-Related Restrictions on the Prevalence of Overweight and Obese Czech Children. Int J Environ Res Public Health. 2022;19(19):11902. Go to original source... Go to PubMed...
    6. Forzano I, Varzideh F, Avvisato R, et al. Tirzepatide: A Systematic Update. Int J Mol Sci. 2022;23(23):14631. Go to original source... Go to PubMed...
    7. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet Lond Engl. 2021;398(10295):143-155. Go to original source... Go to PubMed...
    8. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet Lond Engl. 2021;398(10300):583-598. Go to original source... Go to PubMed...
    9. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Lond Engl. 2021;398(10313):1811-1824. Go to original source... Go to PubMed...
    10. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. Go to original source... Go to PubMed...
    11. Ghoneim S. Tirzepatide: A New Anti-Obesity Medication. Gastroenterology. 2023;164(1):159. Go to original source... Go to PubMed...
    12. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. Go to original source... Go to PubMed...
    13. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Go to original source... Go to PubMed...
    14. Zhang X, Wang M, Wang X, et al. Comparison of New Glucose-Lowering Drugs on the Risk of Pancreatitis in Type 2 Diabetes: A Network Meta-Analysis. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2022;28(3):333-341. Go to original source... Go to PubMed...
    15. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6. Go to original source... Go to PubMed...
    16. Nakatani Y, Kawabe A, Matsumura M, et al. Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabetes Care. 2016;39(2):e22-23. Go to original source... Go to PubMed...
    17. Urva S, Quinlan T, Landry J, et al. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2021;60(8):1049-1059. Go to original source... Go to PubMed...
    18. Urva S, Quinlan T, Landry J, et al. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2022;61(7):1057-1067. Go to original source... Go to PubMed...
    19. Ordóñez-Vázquez AL, Beltrán-Gall SM, Pal SC, et al. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Med Sci Monit Int Med J Exp Clin Res. 2022;28:e938365. Go to original source... Go to PubMed...
    20. Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393-406. Go to original source... Go to PubMed...
    21. Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66. Go to original source... Go to PubMed...
    22. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Go to original source... Go to PubMed...
    23. Patoulias D, Papadopoulos C, Fragakis N, et al. Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide. Am J Cardiol. 2022;181:139-140. Go to original source... Go to PubMed...
    24. Lingvay I, Cheng AY, Levine JA, et al. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to-5 studies. Diabetes Obes Metab. 2023;25(4):965-974. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.